LPP strapline

Trastuzumab Biosimilar

Applicable to all London trusts providing cancer services.

Benefits of the contract

LPP is currently monitoring the uptake of biosimilar trastuzumab and the cost savings achieved within London due to this change. The volumes are taken from IQVIA and Define databases. The contract is owned by the Commercial Medicines Unit.

Contract Overview
Start 01-04-18
End 31-03-19
Contract Type Pricing Agreement
Accessible to All LPP London members
Authority London Procurement Partnership (GSTT)
OJEU Award Ref
Initial Period (Years) 2.00
Extensions remaining 0.00
LPP Contact Jackie Eastwood
07500 573068
LPP Ref Trastuzumab